IFNB1 and myeloid sarcoma: Multiple sclerosis (MS) is a chronic disorder of the central nervous system, which, as a result of autoimmune attacks on the neural tissue, classically damages the macular degeneration of the axon and leads to the formation of polygonal lesions in the white matter.1-3 MS is phenotypically divided into several groups, the most common of which is the relapsing-remitting multiple sclerosis (RRMS).3 Despite the recent advances in the treatment of MS, interferon beta (IFN-β) still has the highest levels of prescription drug among immunosuppressive drugs for RRMS patients.1